Angiotech wins before the UK House of Lords



    VANCOUVER, July 10 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company,
announced that yesterday, the highest court of the United Kingdom, the House
of Lords, confirmed in a precedent-setting decision the validity of one of
Angiotech's patents related to its paclitaxel stent inventions. As Lord
Neuberger of Abbotsbury, commented, "The decision represents a significant
development in the United Kingdom patent law".
    "We are pleased that the House of Lords entered final judgment in
Angiotech's favor and view this outcome as further proof of the continued
strength of our paclitaxel stent patent portfolio throughout the world," said
Dr. Bill Hunter, President and CEO of Angiotech. "We remain committed to
vigorously protecting our proprietary technologies and defending our
intellectual property, and reaching supportive conclusion on this decision
reaffirms this commitment," added Dr. Hunter.
    The patent at issue was granted to Angiotech Pharmaceuticals Inc. by the
European Patent Office (the "EPO") on June 25, 1997. At the EPO, five
different companies opposed the patent. After over nine years of legal battles
their challenge proved unsuccessful and the validity of the patent was
maintained. On February 1, 2005, Angiotech commenced suit against Conor
Medsystems Inc. ("Conor") in the Netherlands. Conor responded by commencing
proceedings in the UK to revoke the patent. Conor argued that, as of July 1993
(the priority date), the claims in the patent lacked inventive step (i.e.,
were obvious) under UK law.
    Both the UK trial court and the UK Court of Appeal decided that the
patent was invalid in view of several publications. Within the same time frame
several courts in the Netherlands, following the approach of the EPO and
concluded that Angiotech's claimed invention was inventive and not obvious in
view of the same publications. Angiotech appealed the UK lower court decisions
to the House of Lords seeking to resolve these inconsistent outcomes.
    In his lead opinion upholding the validity of Angiotech's patent, Lord
Hoffmann did not agree with the reasoning that the UK lower courts used in
justifying revocation and instead agreed with the opinion of the Dutch Court.
The House of Lords' unanimous decision reflects an important development in
bringing uniformity to the interpretation of the European Patent Convention
among the national courts of Europe and the European Patent Office.

    Note on Forward Looking Statements:

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2007 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research development and
product and drug development. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Page 1 of 2 Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these forward-looking
statements and include, among others, the following: general economic and
business conditions, both nationally and in the regions in which we operate;
market demand; technological changes that could impact our existing products
or our ability to develop and commercialize future products; competition;
existing governmental regulations and changes in, or the failure to comply
with, governmental regulations; adverse results or unexpected delays in drug
discovery and clinical development processes; decisions, and the timing of
decisions, made by health regulatory agencies regarding approval of our
technology and products; the requirement for substantial funding to conduct
research and development and to expand commercialization activities or
consummate acquisitions; and any other factors that may affect performance. In
addition, our business is subject to certain operating risks that may cause
the actual results expressed or implied by the forward-looking statements in
this report to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete preclinical and clinical development of our
products; changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection resulting
from third party challenges to our patents; commercialization limitations
imposed by patents owned or controlled by third parties; our ability to obtain
rights to technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce timely patent
and other intellectual property protection for our technology and products;
the ability to enter into, and to maintain, corporate alliances relating to
the development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; our ability to continue to integrate into
our business the operations of American Medical Instruments Holdings, Inc.
("AMI"); our ability to achieve the operational and other synergies and the
other commercial or financial benefits expected as a result of the acquisition
of AMI; and any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory authorities
or the SEC.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.





For further information:

For further information: Sage Baker, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6933,
sbaker@angio.com; Elizabeth Sol, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6920,
esol@angio.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890